Sustained generation and survival of antigen-specific CD62Lhigh CD8+ T-cells through in vitro conditioning with interleukin-12: Implications for anti-tumor adoptive immunotherapy.

被引：0
|
作者：
Diaz-Montero, C. Marcela [1 ]
Kadima, Andre [1 ]
El-Naggar, Sabry A. [1 ]
Nath, Narender [1 ]
Cole, David J. [1 ]
Salem, Mohamed L. [1 ]
机构：
[1] Med Univ South Carolina, Charleston, SC 29425 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5578
引用
收藏
页数：2
相关论文
共 49 条
  • [1] Generating Potent Anti-Tumor CD62Lhigh CD8+T Cells for Adoptive Immunotherapy
    Yang, Shicheng
    Zhang, Ling
    Zheng, Zhili
    Park, Tristen
    Rosenberg, Steven A.
    Morgan, Richard A.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 866 - 867
  • [2] Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells
    Mark P. Rubinstein
    Ee Wern Su
    Samantha Suriano
    Colleen A. Cloud
    Kristina Andrijauskaite
    Pravin Kesarwani
    Kristina M. Schwartz
    Katelyn M. Williams
    C. Bryce Johnson
    Mingli Li
    Gina M. Scurti
    Mohamed L. Salem
    Chrystal M. Paulos
    Elizabeth Garrett-Mayer
    Shikhar Mehrotra
    David J. Cole
    Cancer Immunology, Immunotherapy, 2015, 64 : 539 - 549
  • [3] Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells
    Rubinstein, Mark P.
    Su, Ee Wern
    Suriano, Samantha
    Cloud, Colleen A.
    Andrijauskaite, Kristina
    Kesarwani, Pravin
    Schwartz, Kristina M.
    Williams, Katelyn M.
    Johnson, C. Bryce
    Li, Mingli
    Scurti, Gina M.
    Salem, Mohamed L.
    Paulos, Chrystal M.
    Garrett-Mayer, Elizabeth
    Mehrotra, Shikhar
    Cole, David J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (05) : 539 - 549
  • [4] FULLY AUTOMATED GENERATION OF ANTIGEN-SPECIFIC CD4+AND CD8+T CELLS FOR ADOPTIVE IMMUNOTHERAPY
    Fahrendorff, Melanie
    von Oppen, Nanette
    Rauser, Georg
    Assenmacher, Mario
    Biehl, Martin
    Miltenyi, Stefan
    TRANSPLANT INTERNATIONAL, 2011, 24 : 334 - 335
  • [5] Optimum in vitro expansion of human antigen-specific CD8+ T cells for adoptive transfer therapy
    Montes, M
    Rufer, N
    Appay, V
    Reynard, S
    Pittet, MJ
    Speiser, DE
    Guillaume, P
    Cerottini, JC
    Romero, P
    Leyvraz, S
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 142 (02): : 292 - 302
  • [6] TGF-β1 Induces Preferential Rapid Expansion and Persistence of Tumor Antigen-specific CD8+ T Cells for Adoptive Immunotherapy
    Liu, Shujuan
    Etto, Tamara
    Rodriguez-Cruz, Tania
    Li, Yufeng
    Wu, Chenghan
    Fulbright, Orenthial J.
    Hwu, Patrick
    Radvanyi, Laszlo
    Lizee, Gregory
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (04) : 371 - 381
  • [7] Efficient and Rapid In Vitro Generation of Multi-Virus-Specific CD4+ and CD8+ T Cells for Adoptive Immunotherapy
    Richter, Anne
    Foerster, Anna
    Lasmanowicz, Verena
    Brauns, Olaf
    Kramer, Sven
    Jekow, Petra
    Roenspeck, Wolfgang
    Assenmacher, Mario
    BLOOD, 2010, 116 (21) : 506 - 506
  • [8] In vitro activated CD4+ T cells are less susceptible than naive T cells to lymphoma-induced antigen-specific tolerance:: Implications for adoptive immunotherapy.
    Sotomayor, EM
    Borrello, I
    Tubb, E
    Levitsky, HI
    BLOOD, 1998, 92 (10) : 245A - 245A
  • [9] Regeneration of adenovirus specific T-cells in children after allogeneic stem cell transplantation and efficient generation of CD4+ and CD8+ T-cells for specific adoptive immunotherapy
    Feuchtinger, T
    Einsele, H
    Hamprecht, K
    Schumm, M
    Lücke, J
    Greil, J
    Niethammer, D
    Lang, P
    BONE MARROW TRANSPLANTATION, 2003, 31 : S209 - S209
  • [10] Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy
    Borchers, S.
    Masslo, C.
    Mueller, C. A.
    Tahedl, A.
    Volkind, J.
    Nowak, Y.
    Umansky, V.
    Esterlechner, J.
    Frank, M. H.
    Ganss, C.
    Kluth, M. A.
    Utikal, J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 191 (01): : 74 - 83
12345